The market seems to have forgotten these upcoming catalysts:Q1 2019 - aGVHD BLA filed with FDA .
Q1 2019 - Meeting with FDA to discuss filing of BLA under RMAT for phase 2b LVAD - SI is confident FDA will accept a BLA for efficacy in GI bleeding alone (and so am I).
Q1 2019 - has everyone forgotten that CLBP phase 3 trial completed enrollment in Q1 2018; so 12-months results are due in March 2019 (we will have to wait another year for 24-month results, but could be good enough to put it back in the radar)
Q2 2019 - BLA filing with FDA for LVAD (hopeful). If done, then approval in Q3 under RMAT.
Q3 2019 - FDA approves aGVHD (this is a done deal). Revenues from sales should start in September 2019.
Q4 2019 - revenues start for LVAD treatment.
Q1 2020 - 12-month topline data for CHF phase 3 trial.
Q2 2020 - Mesoblast sold for USD 20 billion (my prediction).
Cheers.
- Forums
- ASX - By Stock
- MSB
- MSB Trading - 2019
MSB Trading - 2019, page-57
-
-
- There are more pages in this discussion • 4,368 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.5¢ |
Change
0.005(0.52%) |
Mkt cap ! $1.121B |
Open | High | Low | Value | Volume |
96.5¢ | 99.5¢ | 96.5¢ | $1.775M | 1.815M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
33 | 205094 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 126409 | 56 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 200656 | 0.970 |
19 | 193635 | 0.965 |
14 | 151139 | 0.960 |
9 | 512017 | 0.955 |
8 | 57365 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 115275 | 55 |
0.980 | 149231 | 20 |
0.985 | 118211 | 11 |
0.990 | 96005 | 15 |
0.995 | 159522 | 7 |
Last trade - 15.06pm 26/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |